Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01414283 (Clinical Trial / PSMA ADC)

Study Title
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer (NCT01414283)

Trial Description
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.

This trial is sponsored by Progenics Pharmaceuticals [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
    • Drugs used in this trial
      • PSMA ADC
  • Phase: I
  • Enrollment: 52
  • Start: October 2008
  • Study Completion: September 2013
  • Last verified: October 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 13, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar